Prognostic value of baculoviral IAP repeat containing 5 expression as a new biomarker in lung adenocarcinoma: a meta-analysis

ABSTRACT

Background

BIRC5 is associated with the prognosis of a variety of tumors. This meta-analysis aimed to identify whether BIRC5 is associated with the prognosis of lung adenocarcinoma (LUAD).

Research Design and Methods

We conducted an in-depth review of seven Chinese and English databases and two high-throughput sequencing databases according to inclusion and exclusion criteria to find relevant studies. The pooled standardized mean differences (SMDs) and 95% confidence intervals (CIs) for the associations between the BIRC5 expression level and clinicopathological characteristics were calculated, and the pooled hazard ratios (HRs) and 95% CIs were calculated to estimate associations between the BIRC5 expression level and survival outcomes.

Results

In total, 17 studies involving 2887 LUAD patients whose BIRC5 expression level was known were included in this meta-analysis. The BIRC5 expression level was higher in younger patients, males, and smokers and correlated with advanced AJCC, T and N stages but not M stage. A high BIRC5 expression level also correlated with poor overall survival (OS) and progression-free survival (PFS). There was no publication bias in this study.

Conclusions

This meta-analysis indicates that BIRC5 is a significant biomarker for a poor prognosis and poor clinicopathological outcomes in patients with LUAD.

KEYWORDS:

• BIRC5
• prognosis
• meta-analysis
• lung adenocarcinoma
• TCGA

Ethical Approval

All analyses in the current study were aligned with established medical ethics guidelines.

Informed Consent

The current study is based on a publicly available dataset. Thus, informed consent was not needed.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Author Contributions

D He conceived and designed the study and wrote the manuscript. K Huang and Z Liang contributed to data analysis and manuscript preparation.

Data Availability Statement

RNA-seq and clinical information for each sample were downloaded from the GEO website (https://www.ncbi.nlm.nih.gov/geo/) and the TCGA website (https://portal.gdc.cancer.gov/).

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Acknowledgments

We would like to thank American Journal Experts for their assistance with language editing.

SUPPLEMENTARY MATERIAL

Supplemental data for this article can be accessed here.

Additional information

Funding

This study was supported by the National Natural Science Foundation of China (82072156) and the Science and Technology Department of Sichuan Province (2018JY0389 and 2019YFS0443).